Positive Preclinical Data for ARG-007 Neuroprotection in HIE
Filed with ASX · · 6 pages · English
• ARG-007 shown to offer neuroprotection for late pre-term hypoxic-ischaemic encephalopathy (HIE), providing further evidence that the technology could have greater applications beyond stroke. • HIE is a type of brain dysfunction that occurs when the brain doesn't receive enough oxygen or blood flow for a period of time. It is one of the most serious birth complications for infants. • In an animal
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Phase 1 Clinical Trial Overview & Roadmap
- Argenica Partners With Linear For Phase 1 Clinical Trial
- Argenica Achieves Manufacturing Milestones
- Appendix 4E & Annual Report 30 June 2021
- Grant Secured to Advance Pre-Clinical Studies Of ARG-007
Later from Argenica Therapeutics
- Argenica to be Granted Patent Protection in the US
- Preliminary Pre-Clinical Tox Studies Successfully Completed
- Successful Completion of Final GLP Genotoxicity Studies
- Peer Reviewed Paper Published on Preclinical Study
- Positive Preclincal Data on Efficacy in New Indication
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics